Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the
Maria-Victoria Mateos1, Katja Weisel2, Joris Diels3
1Hospital Clínico Universitario de Salamanca, Salamanca, Spain.
Background:
Despite advances in treatments for multiple myeloma (MM), most patients relapse and become refractory to standard drug classes including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 antibodies. The LocoMMotion study showed poor clinical outcomes in triple-class exposed patients with relapsed/refractory MM (RRMM) treated with real-world clinical practice (RWCP) therapy. Here, we report efficacy outcomes for Spanish patients receiving RWCP treatments in the LocoMMotion study compared with the full cohort.
Patients And Methods:
The prospective, noninterventional, multinational LocoMMotion study (NCT04035226) enrolled 248 patients who had received ≥ 3 prior lines of therapy (LOT), including a PI, an IMiD, and an anti-CD38 antibody, with disease progression during or after their last LOT. The primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS) and overall survival (OS).
Results:
Spanish patients (n = 24) had received a median of 4 prior LOT (range, 2-7). At 29.2 months median follow-up, patients had received 14 different treatment regimens used in RWCP during the study. Efficacy outcomes were consistent between the Spanish cohort and overall study population. The ORR was 29.2% (95% CI, 12.6%-51.1%). Median PFS and OS were 4.6 months (95% CI, 1.2-6.3) and 11.6 months (95% CI, 6.4-24.5), respectively.
Conclusion:
Spanish patients from the LocoMMotion study demonstrated poor outcomes in response to RWCP treatments consistent with those of the overall study population, highlighting the need for access to new and effective therapies for patients with RRMM in Spain and globally.
Insights
Outcomes for Spanish patients with relapsed/refractory multiple myeloma (RRMM) receiving real-world clinical practice (RWCP) therapy were poor, mirroring the overall LocoMMotion study findings. This highlights an urgent need for novel treatments for RRMM patients in Spain and worldwide.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Multiple myeloma (MM) treatment advances still result in relapse and refractoriness to standard therapies like immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 antibodies.
- The LocoMMotion study previously indicated poor outcomes for triple-class exposed patients with relapsed/refractory MM (RRMM) under real-world clinical practice (RWCP).
Purpose of the Study:
- To report the efficacy outcomes of Spanish patients within the LocoMMotion study receiving RWCP treatments.
- To compare the efficacy of RWCP treatments in Spanish RRMM patients to the full LocoMMotion study cohort.
Main Methods:
- The study involved 248 patients in a prospective, noninterventional, multinational LocoMMotion study (NCT04035226).
- Patients had received at least 3 prior lines of therapy (LOT), including a PI, an IMiD, and an anti-CD38 antibody, with disease progression on or after their last LOT.
- Primary endpoint was overall response rate (ORR); secondary endpoints included progression-free survival (PFS) and overall survival (OS).
Main Results:
- Twenty-four Spanish patients had received a median of 4 prior LOT (range, 2-7).
- After a median follow-up of 29.2 months, efficacy outcomes for Spanish patients were consistent with the overall study population.
- The overall response rate (ORR) was 29.2% (95% CI, 12.6%-51.1%), with median progression-free survival (PFS) of 4.6 months (95% CI, 1.2-6.3) and median overall survival (OS) of 11.6 months (95% CI, 6.4-24.5).
Conclusions:
- Spanish patients with RRMM in the LocoMMotion study experienced poor outcomes with RWCP treatments.
- These findings are consistent with the overall study population, underscoring the critical need for improved and novel therapeutic options for RRMM patients in Spain and globally.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015